Press release

15 December 2020 - The biomedical shared service model to accelerate medical innovations of the Chemelot Institute for Science and Technology (InSciTe) has been acknowledged at European level.

Interreg europe project Medtech4 Europe

The Interreg europe project Medtech4 Europe validated this model as best practice on how to make Europe more innovative and attractive in health research and development. InSciTe’s approach of joint development in a shared biomedical lab, where experts from companies and academia work side-by-side, has shown to be a creative and very successful way of accelerating medical innovation.

Fast track to clinic 
The InSciTe biomedical program aims to develop solutions for future healthcare and wellbeing for an aging population. However, many medical innovations that could provide solutions never reach the clinic and the patients, simply because it is too costly, and too time consuming. InSciTe selects the most promising innovations and provides a fast-track to the clinic. The institute guides research consortia in their product development and reduces the time to market with more than a year. InSciTe also helps to set up startups, for instance for the knee implant ‘SyCap’ which will be used to replace local cartilage damage in the knee of patients. The biomedical shared services model of InSciTe itself has also led to a new business model, which is now commercially exploited by spin off Medace.   

Innovation in health 
New medical technologies are key for the future by providing solutions to increase wellbeing and reduce healthcare costs in a context of ageing population. MedTech is one of the most innovative high-tech sectors. It is also a highly multidisciplinary sector, and globally highly competitive in science and business, requiring a high speed of development towards application in the clinic. Solutions for sustainable healthcare is one of the main innovation themes of the Limburg region. InSciTe shows how public-private partnerships can accelerate medical innovations through new collaborations and by providing shared infrastructures and services. This also clearly shows the value of the regional eco-system that is established in Limburg around the four Brightlands campuses where InSciTe is located in the heart of the medical hub at the Brightlands Maastricht Health Campus.

Emiel Staring, Managing Director of InSciTe: ‘We are very happy that our InSciTe way of working is recognized as a best practice to speed up the development and clinical application of promising new medical innovations. Our concept can also be applied in other regions to further regional social and economic development.’   

Public-private institute as an answer to Limburg’s challenges 
The Chemelot Institute for Science & Technology (InSciTe) was initiated by DSM, University of Maastricht & Maastricht UMC+, Technological University of Eindhoven and the Province of Limburg, as part of their triple helix program. InSciTe offers shared services and infrastructure to promote the development of new, smart biomedical applications. InSciTe is located at the Brightlands Maastricht Health Campus, where it will use Medace's brand new biomedical lab and office facilities. 

Share:

European acknowledgement for (bio)medical acceleration model InSciTe  

Chemelot InSciTe